(Q35953361)

11 August 2017

Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). (English)

1 reference

11 August 2017

1 reference

1

Russell E Ware

1 reference

11 August 2017

Ronald W Helms

2

1 reference

PMCID

3350359

11 August 2017

SWiTCH Investigators

series ordinal

3

1 reference

PMCID

3350359

11 August 2017

language of work or name

English

0 references

publication date

7 February 2012

1 reference

11 August 2017

1 reference

11 August 2017

119

1 reference

11 August 2017

3925-3932

1 reference

11 August 2017

17

1 reference

Stroke With Transfusions Changing to Hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload

11 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3350359

Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG).

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3350359

Silent cerebral infarcts occur despite regular blood transfusion therapy after first strokes in children with sickle cell disease

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3350359

Transcranial Doppler ultrasonography and prophylactic transfusion program is effective in preventing overt stroke in children with sickle cell disease

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3350359

How I use hydroxyurea to treat young patients with sickle cell anemia

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3350359

R2* magnetic resonance imaging of the liver in patients with iron overload

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3350359

Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3350359

Longitudinal analysis of heart and liver iron in thalassemia major

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3350359

Systematic review: Hydroxyurea for the treatment of adults with sickle cell disease

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3350359

Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3350359

Risk of recurrent stroke in children with sickle cell disease receiving blood transfusion therapy for at least five years after initial stroke

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3350359

Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3350359

High risk of recurrent stroke after discontinuance of five to twelve years of transfusion therapy in patients with sickle cell disease

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3350359

Stroke in sickle cell disease: demographic, clinical, and therapeutic considerations

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3350359

Stroke in a cohort of patients with homozygous sickle cell disease

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3350359

Long-term results using hydroxyurea/phlebotomy for reducing secondary stroke risk in children with sickle cell anemia and iron overload

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3350359

Impact of early transcranial Doppler screening and intensive therapy on cerebral vasculopathy outcome in a newborn sickle cell anemia cohort

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3350359

Treatment outcome in a cohort of young patients with polycythemia vera

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3350359

Hydroxyurea for children with sickle cell disease

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3350359

Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3350359

Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3350359

Phlebotomy to reduce iron overload in patients cured of thalassemia by bone marrow transplantation. Italian Cooperative Group for Phlebotomy Treatment of Transplanted Thalassemia Patients

24 September 2018

1 reference

12 December 2020

Hydroxyurea: An alternative to transfusion therapy for stroke in sickle cell anemia

1 reference

12 December 2020

Erythrocyte autoantibodies in paediatric patients with sickle cell disease receiving transfusion therapy: frequency, characteristics and significance

1 reference

12 December 2020

Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease

1 reference

12 December 2020

Cerebrovascular accidents in sickle cell disease: rates and risk factors

1 reference

12 December 2020

Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease

1 reference

12 December 2020

Bone marrow transplantation versus periodic prophylactic blood transfusion in sickle cell patients at high risk of ischemic stroke: a decision analysis

1 reference

12 December 2020

Iron overload is a determinant of morbidity and mortality in adult patients with sickle cell disease

1 reference

12 December 2020

The natural history of stroke in sickle cell disease

1 reference

12 December 2020

Efficacy of transfusion therapy for one to two years in patients with sickle cell disease and cerebrovascular accidents

1 reference

12 December 2020

Transfusion and alloimmunization in sickle cell disease. The Cooperative Study of Sickle Cell Disease

1 reference

12 December 2020

Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions

1 reference

12 December 2020

10.1182/BLOOD-2011-11-392340

Identifiers

DOI

1 reference

11 August 2017

1 reference

11 August 2017

1 reference

PMCID

3350359